Skip to Content

KRAS inhibitor sotorasib may become the new standard for advanced NSCLC with KRAS mutations

In the Phase II CodeBreak 100 study, sotorasib has shown clinically durable benefit with a favorable adverse event profile in patients with KRAS p.G12C mutations who have previously received up to 3 treatments for NSCLC. At ESMO 2020, sotorasib surprised in the phase I study and in his presentation at the WCLC 2020 Presidential Symposium, Dr Bob Li of Memorial Sloan Kettering Cancer Center presented positive phase II results.

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top